Table 1.
Numbers and proportions of individuals with chronic obstructive pulmonary disease prescribed initial pharmacotherapy per treatment group within 90 days postdiagnosis in Dutch primary care, overall and stratified by age and sex, from 2010–2021
| Total (N = 54,628) |
Females (N = 25,312) |
Males (N = 29,316) |
|||||
|---|---|---|---|---|---|---|---|
| 40–64 years (N = 13,024) |
65–79 years (N = 9544) |
≥ 80 years (N = 2744) |
40–64 years (N = 13,222) |
65–79 years (N = 12,780) |
≥ 80 years (N = 3314) |
||
| No prescriptions | 19,860 (36.4) | 4720 (36.2) | 3144 (32.9) | 790 (28.8) | 5467 (41.3) | 4662 (36.5) | 1077 (32.5) |
| SABA# | 6041 (11.1) | 1860 (14.3) | 1017 (10.7) | 267 (9.7) | 1528 (11.6) | 1081 (8.5) | 288 (8.7) |
| SAMA# | 2225 (4.1) | 441 (3.4) | 458 (4.8) | 216 (7.9) | 359 (2.7) | 566 (4.4) | 185 (5.6) |
| SABA-SAMA# | 459 (0.8) | 75 (0.6) | 88 (0.9) | 42 (1.5) | 85 (0.6) | 119 (0.9) | 50 (1.5) |
| SABA-SAMA | 457 (0.8) | 75 (0.6) | 88 (0.9) | 42 (1.5) | 85 (0.6) | 117 (0.9) | 50 (1.5) |
| SABA-SAMA, Xanthines | 2 (0.0) | – | – | – | – | 2 (0.0) | – |
| LABA | 2080 (3.8) | 464 (3.6) | 413 (4.3) | 133 (4.8) | 429 (3.2) | 488 (3.8) | 153 (4.6) |
| LABA | 1879 (3.4) | 417 (3.2) | 366 (3.8) | 117 (4.3) | 392 (3.0) | 450 (3.5) | 137 (4.1) |
| LABA, SABA | 122 (0.2) | 33 (0.3) | 23 (0.2) | 9 (0.3) | 27 (0.2) | 21 (0.2) | 9 (0.3) |
| LABA, SABA Xanthines | 1 (0.0) | 1 (0.0) | – | – | – | – | – |
| LABA, SAMA | 66 (0.1) | 10 (0.1) | 22 (0.2) | 7 (0.3) | 9 (0.1) | 13 (0.1) | 5 (0.2) |
| LABA, SABA-SAMA | 12 (0.0) | 3 (0.0) | 2 (0.0) | - | 1 (0.0) | 4 (0.0) | 2 (0.1) |
| LAMA | 9426 (17.3) | 1896 (14.6) | 1809 (19.0) | 517 (18.8) | 2023 (15.3) | 2528 (19.8) | 653 (19.7) |
| LAMA | 8709 (15.9) | 1725 (13.2) | 1665 (17.4) | 482 (17.6) | 1859 (14.1) | 2375 (18.6) | 603 (18.2) |
| LAMA, SABA | 580 (1.1) | 151 (1.2) | 109 (1.1) | 27 (1.0) | 142 (1.1) | 118 (0.9) | 33 (1.0) |
| LAMA, SAMA | 101 (0.2) | 14 (0.1) | 24 (0.3) | 6 (0.2) | 18 (0.1) | 27 (0.2) | 12 (0.4) |
| LAMA, SABA-SAMA | 34 (0.1) | 6 (0.0) | 11 (0.1) | 2 (0.1) | 3 (0.0) | 7 (0.1) | 5 (0.2) |
| LAMA, Xanthines | 2 (0.0) | – | – | – | 1 (0.0) | 1 (0.0) | – |
| LABA-LAMA | 2324 (4.3) | 417 (3.2) | 509 (5.3) | 104 (3.8) | 495 (3.7) | 631 (4.9) | 168 (5.1) |
| LABA-LAMA | 2043 (3.7) | 351 (2.7) | 445 (4.7) | 89 (3.2) | 435 (3.3) | 572 (4.5) | 151 (4.6) |
| LABA-LAMA, SABA | 201 (0.4) | 51 (0.4) | 36 (0.4) | 12 (0.4) | 46 (0.3) | 45 (0.4) | 11 (0.3) |
| LABA-LAMA, SABA, Xanthines | 1 (0.0) | – | – | – | 1 (0.0) | – | – |
| LABA-LAMA, SAMA | 26 (0.0) | 7 (0.1) | 9 (0.1) | – | 5 (0.0) | 3 (0.0) | 2 (0.1) |
| LABA-LAMA, SAMA, Xanthines | 1 (0.0) | – | 1 (0.0) | – | – | – | – |
| LABA-LAMA, SABA-SAMA | 51 (0.1) | 8 (0.1) | 18 (0.2) | 3 (0.1) | 7 (0.1) | 11 (0.1) | 4 (0.1) |
| LABA-LAMA, Xanthines | 1 (0.0) | – | – | – | 1 (0.0) | – | – |
| LABA-ICS | 7508 (13.7) | 1940 (14.9) | 1278 (13.4) | 439 (16.0) | 1801 (13.6) | 1580 (12.4) | 470 (14.2) |
| LABA-ICS | 6370 (11.7) | 1598 (12.0) | 1088 (11.0) | 366 (13.0) | 1551 (11.0) | 1374 (10.0) | 393 (11.0) |
| LABA-ICS, SABA | 786 (1.4) | 274 (2.1) | 120 (1.3) | 37 (1.3) | 201 (1.5) | 121 (0.9) | 33 (1.0) |
| LABA-ICS, SABA, Xanthines | 3 (0.0) | 1 (0.0) | - | - | 1 (0.0) | - | - |
| LABA-ICS, SAMA | 249 (0.5) | 50 (0.4) | 48 (0.5) | 29 (1.1) | 33 (0.2) | 60 (0.5) | 29 (0.9) |
| LABA-ICS, SAMA, Xanthines | 5 (0.0) | - | 1 (0.0) | 1 (0.0) | 1 (0.0) | 1 (0.0) | 1 (0.0) |
| LABA-ICS, SABA-SAMA | 92 (0.2) | 17 (0.1) | 19 (0.2) | 6 (0.2) | 14 (0.1) | 22 (0.2) | 14 (0.4) |
| LABA-ICS, SABA-SAMA, Xanthines | 1 (0.0) | - | – | – | – | 1 (0.0) | – |
| LABA-ICS, Xanthines | 2 (0.0) | 1 (0.0) | – | – | – | 1 (0.0) | – |
| LABA-LAMA-ICS | 2402 (4.4) | 557 (4.3) | 435 (4.6) | 94 (3.4) | 499 (3.8) | 675 (5.3) | 142 (4.3) |
| LABA-LAMA-ICS | 1986 (3.6) | 452 (3.5) | 353 (3.7) | 75 (2.7) | 386 (2.9) | 586 (4.6) | 134 (4.0) |
| LABA-LAMA-ICS, SABA | 330 (0.6) | 85 (0.7) | 64 (0.7) | 14 (0.5) | 95 (0.7) | 65 (0.5) | 7 (0.2) |
| LABA-LAMA-ICS, SAMA | 38 (0.1) | 9 (0.1) | 9 (0.1) | 2 (0.1) | 7 (0.1) | 11 (0.1) | – |
| LABA-LAMA-ICS, SAMA, Xanthines | 1 (0.0) | – | – | – | – | 1 (0.0) | – |
| LABA-LAMA-ICS, SABA-SAMA | 38 (0.1) | 9 (0.1) | 8 (0.1) | 2 (0.1) | 10 (0.1) | 8 (0.1) | 1 (0.0) |
| LABA-LAMA-ICS, SABA-SAMA, Xanthines | 2 (0.0) | 1 (0.0) | – | – | 1 (0.0) | – | – |
| LABA-LAMA-ICS, Xanthines | 7 (0.0) | 1 (0.0) | 1 (0.0) | 1 (0.0) | – | 4 (0.0) | – |
| Other | 2303 (4.2) | 654 (5.0) | 393 (4.1) | 142 (5.2) | 536 (4.1) | 450 (3.5) | 127 (3.9) |
| ICS | 1158 (2.1) | 324 (2.5) | 191 (2.0) | 64 (2.3) | 264 (2.0) | 248 (1.9) | 67 (2.0) |
| ICS, SABA | 472 (0.9) | 165 (1.3) | 74 (0.8) | 26 (0.9) | 137 (1.0) | 53 (0.4) | 17 (0.5) |
| ICS, LAMA | 160 (0.3) | 38 (0.3) | 26 (0.3) | 10 (0.4) | 24 (0.2) | 49 (0.4) | 13 (0.4) |
| ICS, SAMA | 87 (0.2) | 18 (0.1) | 19 (0.2) | 10 (0.4) | 14 (0.1) | 18 (0.1) | 8 (0.2) |
| Other | 426 (0.8) | 109 (0.8) | 83 (0.9) | 32 (1.2) | 97 (0.7) | 82 (0.6) | 22 (0.7) |
The data are presented as numbers and percentages, N (%).LABA (long-acting beta-agonists), LAMA (long-acting muscarinic antagonists), ICS (inhaled corticosteroids), SABA (short-acting beta-agonists), SAMA (short-acting muscarinic antagonists). #Reliever-only therapies